Colonization Factor A (BcfA) Elicits Protective Immunity Against Bordetella Bronchiseptica in the Absence of an Additional Adjuvant

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2019 Jul 17

PMID 31308083

Citations 5

Authors

Kacy S Yount

Jamie Jennings-Gee

Kyle Caution

Audra R Fullen

Kara N Corps

Sally Quataert

Rajendar Deora

Purnima Dubey

Affiliations

Soon will be listed here.

Abstract

is an etiologic agent of respiratory diseases in animals and humans. Despite the widespread use of veterinary vaccines, there is limited information on their composition and relative efficacy and on the immune responses that they elicit. Furthermore, human vaccines are not available. We leveraged the dual antigenic and adjuvant functions of colonization factor A (BcfA) to develop acellular vaccines in the absence of an additional adjuvant. BALB/c mice immunized with BcfA alone or a trivalent vaccine containing BcfA and the antigens FHA and Prn were equally protected against challenge with a prototype strain. The trivalent vaccine protected mice significantly better than the canine vaccine Bronchicine and provided protection against a strain isolated from a dog with kennel cough. Th1/17-polarized immune responses correlate with long-lasting protection against bordetellae and other respiratory pathogens. Notably, BcfA strongly attenuated the Th2 responses elicited by FHA and Prn, resulting in Th1/17-skewed responses in inherently Th2-skewed BALB/c mice. Thus, BcfA functions as both an antigen and an adjuvant, providing protection as a single-component vaccine. BcfA-adjuvanted vaccines may improve the efficacy and durability of vaccines against bordetellae and other pathogens.

Citing Articles

Mixed Th1/Th2/Th17 Responses Induced by Plant Oil Adjuvant-Based Vaccine in Mice, with Mechanisms Unraveled by RNA-Seq, 16S rRNA and Metabolomics.

Cui X, Xiang Q, Huang Y, Ji Q, Hu Z, Shi T Vaccines (Basel). 2024; 12(10).

PMID: 39460348 PMC: 11512391. DOI: 10.3390/vaccines12101182.

Eosinophils as drivers of bacterial immunomodulation and persistence.

Parrish K, Gestal M Infect Immun. 2024; 92(9):e0017524.

PMID: 39007622 PMC: 11385729. DOI: 10.1128/iai.00175-24.

Miguelena Chamorro B, De Luca K, Swaminathan G, Longet S, Mundt E, Paul S Clin Microbiol Rev. 2023; 36(3):e0016422.

PMID: 37306571 PMC: 10512794. DOI: 10.1128/cmr.00164-22.

Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces nasal colonization.

Yount K, Hall J, Caution K, Shamseldin M, Guo M, Marion K Front Immunol. 2023; 14:1181876.

PMID: 37275891 PMC: 10232778. DOI: 10.3389/fimmu.2023.1181876.

Safety and Efficacy of the Vaccine Combined with a Vegetable Oil Adjuvant and Multi-Omics Analysis of Its Potential Role in the Protective Response of Rabbits.

Cui X, Xu X, Huang P, Bao G, Liu Y Pharmaceutics. 2022; 14(7).

PMID: 35890330 PMC: 9317422. DOI: 10.3390/pharmaceutics14071434.

References

Charles P, Weber K, Cipriani B, Brosnan C . Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. J Neuroimmunol. 2000; 100(1-2):64-73. DOI: 10.1016/s0165-5728(99)00189-7. View

Dworkin M, Sullivan P, Buskin S, Harrington R, Olliffe J, MacArthur R . Bordetella bronchiseptica infection in human immunodeficiency virus-infected patients. Clin Infect Dis. 1999; 28(5):1095-9. DOI: 10.1086/514761. View

Gopinathan L, Kirimanjeswara G, Wolfe D, Kelley M, Harvill E . Different mechanisms of vaccine-induced and infection-induced immunity to Bordetella bronchiseptica. Microbes Infect. 2007; 9(4):442-8. DOI: 10.1016/j.micinf.2007.01.001. View

Skinner J, Pilione M, Shen H, Harvill E, Yuk M . Bordetella type III secretion modulates dendritic cell migration resulting in immunosuppression and bacterial persistence. J Immunol. 2005; 175(7):4647-52. DOI: 10.4049/jimmunol.175.7.4647. View

Sukumar N, Nicholson T, Conover M, Ganguly T, Deora R . Comparative analyses of a cystic fibrosis isolate of Bordetella bronchiseptica reveal differences in important pathogenic phenotypes. Infect Immun. 2014; 82(4):1627-37. PMC: 3993408. DOI: 10.1128/IAI.01453-13. View

Ellis J, Rhodes C, Lacoste S, Krakowka S . Antibody responses to Bordetella bronchiseptica in vaccinated and infected dogs. Can Vet J. 2014; 55(9):857-64. PMC: 4137927. View

Petrovsky N, Aguilar J . Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004; 82(5):488-96. DOI: 10.1111/j.0818-9641.2004.01272.x. View

Harvill E, Cotter P, Yuk M, Miller J . Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity. Infect Immun. 1999; 67(3):1493-500. PMC: 96485. DOI: 10.1128/IAI.67.3.1493-1500.1999. View

Jennings-Gee J, Quataert S, Ganguly T, DAgostino Jr R, Deora R, Dubey P . The Adjuvant Bordetella Colonization Factor A Attenuates Alum-Induced Th2 Responses and Enhances Bordetella pertussis Clearance from Mouse Lungs. Infect Immun. 2018; 86(6). PMC: 5964531. DOI: 10.1128/IAI.00935-17. View

10.

Ellis J, Krakowka G, Dayton A, Konoby C . Comparative efficacy of an injectable vaccine and an intranasal vaccine in stimulating Bordetella bronchiseptica-reactive antibody responses in seropositive dogs. J Am Vet Med Assoc. 2003; 220(1):43-8. DOI: 10.2460/javma.2002.220.43. View

11.

Szvalb A, Rolston K, Mori N, Tarrand J, Mulanovich V . Infections with the agent of 'kennel cough' in patients with cancer. J Infect. 2018; 78(1):48-53. DOI: 10.1016/j.jinf.2018.07.010. View

12.

Leininger E, Roberts M, Kenimer J, Charles I, Fairweather N, Novotny P . Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci U S A. 1991; 88(2):345-9. PMC: 50807. DOI: 10.1073/pnas.88.2.345. View

13.

Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, Gothefors L . Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology. 1998; 93(1):1-10. PMC: 1364099. DOI: 10.1046/j.1365-2567.1998.00401.x. View

14.

Cherin P, Gherardi R . Macrophagic myofasciitis. Curr Rheumatol Rep. 2000; 2(3):196-200. DOI: 10.1007/s11926-000-0079-6. View

15.

Mosmann T, Coffman R . Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol. 1989; 46:111-47. DOI: 10.1016/s0065-2776(08)60652-5. View

16.

Sacco R, Register K, Nordholm G . Restriction endonuclease analysis discriminates Bordetella bronchiseptica isolates. J Clin Microbiol. 2000; 38(12):4387-93. PMC: 87610. DOI: 10.1128/JCM.38.12.4387-4393.2000. View

17.

Klein N . Licensed pertussis vaccines in the United States. History and current state. Hum Vaccin Immunother. 2014; 10(9):2684-90. PMC: 4975064. DOI: 10.4161/hv.29576. View

18.

Register K . Novel genetic and phenotypic heterogeneity in Bordetella bronchiseptica pertactin. Infect Immun. 2001; 69(3):1917-21. PMC: 98103. DOI: 10.1128/IAI.69.3.1917-1921.2001. View

19.

Vascellari M, Melchiotti E, Bozza M, Mutinelli F . Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas. J Vet Med A Physiol Pathol Clin Med. 2003; 50(6):286-91. DOI: 10.1046/j.1439-0442.2003.00544.x. View

20.

Ausiello C, Lande R, Urbani F, la Sala A, Stefanelli P, Salmaso S . Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun. 1999; 67(8):4064-71. PMC: 96703. DOI: 10.1128/IAI.67.8.4064-4071.1999. View